

Practitioner's Docket No. MBIO99-057CP2M**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Samantha J. Busfield et al.  
 Application No.: 09/503,387 Group: 1644  
 Filed: February 14, 2000 Examiner: HUYNH, PHOUNG N.  
 For: GLYCOPROTEIN VI AND USES THEREOF

Commissioner for Patents  
 Washington, D.C. 20231

**CHANGE OF ATTORNEY DOCKET NUMBER**

Dear Sir:

Please note that the Attorney Docket Number has been changed from 7853-178-999 to MBIO99-057CP2M. Please reference MBIO99-057CP2M on all future correspondence.

Respectfully submitted,

April 14, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By \_\_\_\_\_

*Paul J. Paglierani*  
 Paul J. Paglierani  
 Registration No. 52,498  
 75 Sidney Street  
 Cambridge, MA 02139  
 Telephone - 617-761-6865  
 Facsimile - 617-551-8820

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

Signature \_\_\_\_\_

*Mary MacKinnon*

Date: April 14, 2003

Mary MacKinnon  
(type or print name of person certifying)

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.